Map | A Partnership for Children's Health Search:  Advanced Search
Home General Information Country Support Board Task Forces Resources Media Center
About the Board Last Board Meeting Members Board Reports EC reports Private Access
Printer-friendly format

Quick Reference:

What is GAVI?

GAVI Alliance fact sheets


Board Documents


Press Releases

Immunization Information

Immunization Forum
Latest Issue

GAVI Update



Geneva, Switzerland, 28-29 April 2005
Summary Report

>>Back to the 15th GAVI Board Meeting

  • Ruth Levine, CGD
    PPT - 237K
  • Comment - Roy Widdus, Global Health Futures Network
    PPT - 59K
  • 5. Advance market mechanisms

    • It is clear that industry needs to receive indications about future demand for a vaccine – at the appropriate time when they need it to make their decisions.
    • The proposal provides a foundation for thinking on the possibility of advance market mechanisms. However, a number of issues must be further explored. For example: is it possible to establish in advance the price of a future vaccine? Can suppliers be legally held to an agreement if their actual development cost is not recovered? Would this mechanism really encourage manufacturers by reducing their perceived risk? How would a sole source arrangement work?
    • Advance market mechanisms may only be feasible once the ‘scientific barriers’ are overcome. This is especially relevant for HIV and malaria vaccines.
    • Considering the huge malaria disease burden it will be important for GAVI to maintain a close watch on malaria vaccine development.
    • The potential for advance market mechanisms to speed vaccine development may be enhanced if middle income countries are also considered in the demand scenarios.

    >>Back to the 15th GAVI Board Meeting

    View all presentations here


    1. Global Immunization Vision and Strategy (GIVS)
    2. The Vaccine Fund financial forecast
    3. Looking forward to phase 2; GAVI funding principles
    4. Investment Case review process
    5. Advance market mechanisms
    6. The evolving vaccine pipeline
    7. Long-term vaccine procurement strategy
    8. HepB, Hib and yellow fever in phase 2
    9. Update on the Health System Support (HSS) investment case
    10. Update on the International Finance Facility for Immunization (IFFIm)
    11. 2006-07 GAVI strategic framework and work plan
    12. In camera session
    star_int   Contact us | Guestbook | Copyrights | Text site